ライフサイエンスコーパス: glyburide

1 l activity or by UDP-induced displacement of glyburide.

2 lished by pretreatment with the KATP blocker glyburide.

3 inhibition by low concentrations of ATP and glyburide.

4 by caspase-1 inhibition or the diabetes drug glyburide.

5 tissue explants, an effect also prevented by glyburide.

6 time with rosiglitazone versus metformin or glyburide.

7 rosiglitazone, as compared with metformin or glyburide.

8 iglitazone, 21% with metformin, and 34% with glyburide.

9 it of a reduction in swelling by intravenous glyburide.

10 cardiac myocytes, which could be blocked by glyburide.

11 o alter the inhibition of K(ATP) channels by glyburide.

12 to characterize the in vitro metabolites of glyburide.

13 or absence of metformin or the sulfonylurea glyburide.

14 effects are abolished by the K(ATP) blocker glyburide.

15 s were abolished by the KATP channel blocker glyburide (1 micromol/L).

16 rmin treatment groups; all subjects received glyburide (10 mg BID) as well.

17 Glyburide (10-100 nm) at basal glucose stimulated [3H]th

18 The oral ingestion of glyburide (5 mg) did not change mean arterial pressure (

19 uced relaxation defects were not improved by glyburide (50-300 micromol/l).

20 Glyburide, a K(ATP) channel inhibitor, reproduced the kn

21 Results were consistent for both glyburide (aHR, 1.26 [CI, 1.16 to 1.37]) and glipizide (

22 Glyburide also blocks cytokine-induced eosinophil supero

23 a superoxide dismutase-mimetic agent) and by glyburide (an inhibitor of potassium efflux).

24 imately 3 nM, for an iodinated derivative of glyburide, an anti-diabetic sulfonylurea.

25 Glyburide, an inhibitor of ATP-sensitive K+ channels (K(

26 ges in cytosolic Ca2+, we determined whether glyburide, an inhibitor of K(ATP) channels that stimulat

27 Glyburide analogues inhibit ATP- but not hypothermia-ind

28 was 41 participants who received intravenous glyburide and 36 participants who received placebo.

29 This paper examines the effects of glyburide and 5-HD on K+ flux in isolated, respiring mit

30 w that mitoKATP is completely insensitive to glyburide and 5-HD under the experimental conditions in

31 er hand, mitoKATP became highly sensitive to glyburide and 5-HD when the open state was induced by Mg

32 and for the blocking of cardioprotection by glyburide and 5-hydroxydecanoate (5-HD).

33 Two inhibitors of anion transport, glyburide and ethacrynic acid, blocked maturation of bot

34 were no significant differences between the glyburide and insulin groups in the percentage of infant

35 4.0 years with rosiglitazone, metformin, or glyburide and were examined with periodic metabolic test

36 t by KATP channel blockers, the sulfonylurea glyburide, and the cyanoguanidine N-[1-(3-chlorophenyl)c

37 Interestingly, the effects of glyburide are not antagonized by the ATP-sensitive K+ ch

38 erior glycemic durability over metformin and glyburide as initial monotherapy in type 2 diabetes.

39 We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed ty

40 ed levels of low-, but not high-affinity [3H]glyburide binding in most forebrain areas.

41 g/min in awake rats reduced low-affinity [3H]glyburide binding in numerous hypothalamic and amygdalar

42 In DR-prone rats, low affinity [3H]glyburide binding sites comprised up to 45% of total bin

43 Although Scatchard analysis of [3H]glyburide binding to eosinophil membranes indicated that

44 the number of neurons and high-affinity [3H]glyburide binding was decreased by 20%, while 6-OHDA had

45 By contrast, high affinity [3H]glyburide binding was increased in DR rats throughout th

46 High affinity [3H]glyburide binding was similar between phenotypes.

47 re, glucose often increased low-affinity [3H]glyburide binding, particularly in DR-prone rats at 5 mM

48 Neither 6-OHDA nor 5,7-DHT affected [3H]glyburide binding, while ibotenic acid reduced the numbe

49 Such FC efflux was resistant to glyburide but inhibited by okadaic acid and vanadate.

50 ight gain and edema than either metformin or glyburide but with fewer gastrointestinal events than me

51 rugs such as glibenclamide (adopted US name, glyburide) confer protection against swelling and HT thr

52 N neurons, both 10 mM glucose and 100 microM glyburide decreased the open probability of the Katp cha

53 d high levels of ABC-1 transporter mRNA, and glyburide-dependent PL and FC efflux to apolipoprotein A

54 Specifically, glyburide failed to inhibit spontaneous K[ATP] channel a

55 Given the widespread use of glyburide, further investigation of these differences in

56 The channel blockers glyburide, gadolinium, or tetraethylammonium-Cl did not

57 Glyburide (GLB) is an antidiabetic drug routinely used t

58 ndil, and P1075 or the K(ATP) channel closer glyburide (glibenclamide).

59 the antidiabetic sulfonylurea (SU) compound glyburide (GLY) on energy metabolism, Na(+) flux, insuli

60 Eight women in the glyburide group (4 percent) required insulin therapy.

61 isk of cesarean delivery was 3% lower in the glyburide group (adjusted RR = 0.97; 95% CI, 0.93-1.00).

62 deciliter (5.9+/-0.9 mmol per liter) in the glyburide group and 105+/-18 mg per deciliter (5.9+/-1.0

63 deciliter (6.4+/-1.1 mmol per liter) in the glyburide group and 116+/-22 mg per deciliter (6.5+/-1.2

64 17 (41%) patients in the intravenous glyburide group and 14 (39%) in the placebo group had an

65 (23%) of 44 participants in the intravenous glyburide group and ten (26%) of 39 participants in the

66 rious adverse events (two in the intravenous glyburide group and two in the placebo group, p=1.00).

67 peptide concentrations were increased in the glyburide group compared with glipizide GITS in the 20-m

68 ocate patients to the placebo or intravenous glyburide group.

69 ected in the cord serum of any infant in the glyburide group.

70 Studies on glyburide have indicated that this drug is inactive in i

71 glycemic control compared with metformin and glyburide in patients with recently diagnosed type 2 dia

72 ihyperglycemic durability than metformin and glyburide in patients with recently diagnosed type 2 dia

73 ions from other rats were incubated with [3H]glyburide in the presence of 0, 5 or 10 mM glucose.

74 binding autoradiographically with 20 nM [3H]glyburide in the presence of absence of Gpp(NH)p.

75 nding assessed autoradiographically with [3H]glyburide in the presence or absence of Gpp(NH)p.

76 ceptor autoradiographic binding of 20 nM [3H]glyburide (in the presence or absence of Gpp(NH)p which

77 SUR1 by sulfonylureas such as glibenclamide (glyburide) in conditions as seemingly diverse as stroke

78 [ATP] channels toward the sulfonylurea drug, glyburide, in the presence of cytosolic UDP.

79 e ATP-regulated potassium channel antagonist glyburide increased the rate of [3H]P1075 dissociation i

80 hibited by cotreatment with the KATP blocker glyburide, indicating that the KATP opening is involved

81 Oral glyburide ingestion partially restored CBR-mediated vaso

82 curves were similar at rest before and after glyburide ingestion.

83 The addition of glyburide inhibited diazoxide from increasing outflow fa

84 IL-3 or granulocyte-macrophage CSF overcome glyburide inhibition.

85 The sulfonylurea glyburide inhibits eosinophil survival even at high conc

86 In women with gestational diabetes, glyburide is a clinically effective alternative to insul

87 ggesting that the response of the channel to glyburide is phosphorylation dependent.

88 Therefore, glyburide is the first identified compound to prevent Cr

89 Glyburide is thought to be safe for use during pregnancy

90 In these open states, glyburide (K1/2 values 1-6 microM) and 5-HD (K1/2 values

91 means of green fluorescence probe BODIPY-FL-glyburide labeling of the sulfonylurea receptor of mitoK

92 oculture of eosinophils with combinations of glyburide, lidocaine, and dexamethasone resulted in syne

93 f UDP to antagonize the inhibitory action of glyburide lost after rundown, suggesting that the respon

94 These data demonstrate that, unlike glyburide, metformin provides cardioprotection against H

95 ith GDM, 9173 women (8.3%) were treated with glyburide (n = 4982) or insulin (n = 4191).

96 Depolarization of beta cells with glyburide or 50 m potassium dramatically increased insul

97 Subjects were randomly assigned to glyburide or glipizide gastrointestinal therapeutic syst

98 ween 11 and 33 weeks of gestation to receive glyburide or insulin according to an intensified treatme

99 Treatment with glyburide or insulin during pregnancy within 150 days be

100 -induced insulin release (by glucose, GLP-1, glyburide, or fatty acid) was approximately 60-70% lower

101 and suggest that combination therapies with glyburide, or other inhibitors of the NLRP3 inflammasome

102 an metformin and with less hypoglycemia than glyburide (P<0.001 for all comparisons).

103 ed with metformin, and 63%, as compared with glyburide (P<0.001 for both comparisons).

104 Elevation of [Ca(2+)](i) by glyburide potentiated Erk-1/2 phosphorylation, which was

105 study, we show that the type 2 diabetes drug glyburide prevented activation of the Cryopyrin inflamma

106 ment with nifedipine or the K(ATP) inhibitor glyburide prevented insulin action, further implicating

107 models of stroke have shown that intravenous glyburide reduces brain swelling and improves survival.

108 ast, chronic exposure to elevated glucose or glyburide resulted in progression from G0/G1 to an accum

109 duces significant hyperpolarization which is glyburide-reversed, thus consistent with the activation

110 emic functional recovery in a glibenclamide (glyburide)-reversible manner.

111 These agents were glyburide-reversible potassium channel openers and hyper

112 We assessed whether intravenous glyburide (RP-1127; glibenclamide) would safely reduce b

113 Glyburide's cyclohexylurea group, which binds to adenosi

114 ges in DiBAC(4)(3) fluorescence responses or glyburide-sensitive whole cell currents.

115 t with the role of Cryopyrin in endotoxemia, glyburide significantly delays lipopolysaccharide-induce

116 ed calcium influx in response to glucose and glyburide, suggesting an insulin secretion defect either

117 effect was greater between rosiglitazone and glyburide than between rosiglitazone and metformin.

118 Type 2 diabetic subjects failing glyburide therapy were randomized to receive additional

119 corporation with chronic elevated glucose or glyburide therefore appears to be associated with S phas

120 mized to receive troglitazone 800 mg q.d. or glyburide titrated to achieve glycemic control (< or =20

121 IL1 receptor antagonist to block IL1beta or glyburide to block the Nlrp3 inflammasome results in dec

122 Rosiglitazone was added to insulin or glyburide to improve elevated hemoglobin Hb A1C levels i

123 acid was, however, enhanced in SUR1(-/-) and glyburide-treated SUR1(+/+) islets.

124 efect in type 2 diabetic subjects who failed glyburide treatment by the addition of troglitazone (600

125 r, 4.9 mmol/L [88 mg/dL] for a 20-mg dose of glyburide vs 8.3 mmol/L [150 mg/dL] for placebo; nadir,

126 The risk difference associated with glyburide was 2.97% (95% CI, 1.82-4.12) for neonatal int

127 Glyburide was associated with a lower risk of cardiovasc

128 Intravenous glyburide was given as a 0.13 mg bolus intravenous injec

129 trations were similar in the two groups, and glyburide was not detected in the cord serum of any infa

130 r insulin secretagogues such as arginine and glyburide was similar to that of aP2+/+ mice, arguing ag

131 Intravenous glyburide was well tolerated in patients with large hemi

132 at baseline, newborns of women treated with glyburide were at increased risk for neonatal intensive

133 from privately insured mothers treated with glyburide were more likely to experience adverse outcome

134 ere are limited data on the effectiveness of glyburide when compared with insulin as used in a real-w

135 confidence intervals for the association of glyburide with diagnosis codes for obstetric trauma, ces